Pms63 - Cost-Effectiveness of Actonel® 35 Mg (Risedronate) Gastro-Resistant Tablets for the Treatment of Postmenopausal Women With Osteoporosis in France
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1777
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV